Seamless Therapeutics
Latest round
- Seed
Last raised
- Jul 2022
Total raised
- $13M
Investors
- 2
About Seamless Therapeutics
Based in Dresden, Germany, and founded in 2022 by cofounders Prof. Dr. Frank Buchholz, and Anne-K. Heninger, and Felix Lansing, Seamless Therapeutics GmbH, aka Seamless Therapeutics, provides a gene editing platform to transform the treatment of severe diseases. The company's recombinase platform allows molecular biology tools to unlock the full potential of gene editing, permitting the targeting of any place in the genome to restore health in patients with severe conditions.
Who invested in Seamless Therapeutics
2 investors across 1 round
See all investors in Seamless Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Seed
Jul 21, 2022
Amount
$13M
Investors
Questions about Seamless Therapeutics
Who invested in Seamless Therapeutics?
Seamless Therapeutics has 2 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Seamless Therapeutics raised?
Seamless Therapeutics has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Seamless Therapeutics last raise money?
Seamless Therapeutics's most recent round on record is a Seed, in Jul 2022.
What does Seamless Therapeutics do?
Based in Dresden, Germany, and founded in 2022 by cofounders Prof.
Where is Seamless Therapeutics headquartered?
Seamless Therapeutics is headquartered in Dresden, Germany.
Which VCs invest in companies like Seamless Therapeutics?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Balderton Capital back biotechnology companies at Seamless Therapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Seed
Raising like Seamless Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.